Access count of this item: 182

Files in This Item:
File Description SizeFormat 
29_0357.pdf511.42 kBAdobe PDFView/Open
Title: 表在性膀胱腫瘍に対する膀胱内注入療法におけるcytosine arabinoside(Cylocide)および他剤との併用療法の検討
Other Titles: Study of combination chemotherapy with cytosine arabinoside in the intravesical treatment of superficial bladder tumors
Authors: 吉田, 修  KAKEN_name
宮川, 美栄子  KAKEN_name
渡辺, 泱  KAKEN_name
三品, 輝男  KAKEN_name
小林, 徳朗  KAKEN_name
中川, 清秀  KAKEN_name
福山, 拓夫  KAKEN_name
小倉, 啓司  KAKEN_name
上山, 秀麿  KAKEN_name
伊藤, 坦  KAKEN_name
平竹, 康祐  KAKEN_name
福田, 豊史  KAKEN_name
田端, 義久  KAKEN_name
古澤, 太郎  KAKEN_name
岡村, 和弘  KAKEN_name
内田, 睦  KAKEN_name
前川, 幹雄  KAKEN_name
海法, 裕男  KAKEN_name
田中, 重喜  KAKEN_name
Author's alias: Yoshida, Osamu
Miyakawa, Mieko
Watanabe, Hiroki
Mishina, Teruo
Kobayashi, Tokuro
Nakagawa, Kiyohide
Fukuyama, Takuo
Ogura, Keiji
Ueyama, Hidemaro
Itoh, Hitoshi
Hiratake, Yasuhiro
Fukuda, Toyohumi
Tabata, Yoshihisa
Furusawa, Taro
Okamura, Kazuhiro
Uchida, Mutsumi
Maekawa, Mikio
Kaiho, Hiroo
Tanaka, Shigeki
Keywords: Adult
Carbazilquinone/administration & dosage/adverse effects
Cytarabine/administration & dosage/adverse effects
Drug Evaluation
Drug Therapy, Combination
Middle Aged
Mitomycins/administration & dosage/adverse effects
Urinary Bladder
Urinary Bladder Neoplasms/drug therapy
Zinostatin/administration & dosage/adverse effects
Issue Date: Mar-1983
Publisher: 泌尿器科紀要刊行会
Journal title: 泌尿器科紀要
Volume: 29
Issue: 3
Start page: 357
End page: 364
Abstract: 7機関より得た多発性表在性膀胱腫瘍111症例について,CAおよびCAとMMCまたはNCSまたはCQとの併用による治療効果を検討した.1) CA 400 mg投与29例の有効率は48.3%,CA 200 mgおよびMMC 20 mg併用投与25例の有効率は84.0%,CA 200 mgおよびNCS 4,000 U併用28例は71.4%,CA 200 mgおよびNCS 6,000 U併用22例は95.5%,CA 200 mgおよびCQ 10 mg併用7例は100%の有効率を示し,いずれの場合も併用療法がCA単独よりよい結果である.2)初発症例,再発症例別にみた有効率にはほとんど差をみとめない.3)副作用はいずれも局所刺激症状で,全身障害を示すものはない.CA単独の場合は3.4%, CAにCQを併用した場合がもっとも高く71.4%である.MMCとの併用では40.0%,NCS 4,000 Uとの併用は3.6%,NCS 6,000 Uとの併用の場合は22.7%であった
The effect of instillation therapy using CA alone or in combination with MMC, NCS or CQ was examined in 111 patients (92 males and 19 females, aged 32-87 years old with an average age of 66 years) with multiple superficial bladder tumors. The response rate of 29 patients given CA 400 mg alone was 48.3%, that of 25 patients given combination therapy of CA 200 mg and MMC 20 mg was 84.0%, that of 28 patients given combination therapy of CA 200 mg and NCS 4,000 U was 71.4%, that of 22 patients given combination therapy of CA 200 mg and NCS 6,000 U was 95.5% and that of 7 patients given combination therapy of CA 200 mg and CQ 10 mg was 100%. The response rates of the patients given any of the combination therapies were higher than that of the patients given CA alone. But because MMC, NCS and CQ were not administered singly, combination therapy cannot be concluded to be superior to single therapy. There was little difference between the response rate of primary cases and that of follow up cases. The side effects were all symptoms of local irritation, and were not indicative of systemic damage. Side effects were seen in 3.4%, 71.4%, 40.0% and 3.6% of the patients given CA alone, CA + CQ combination therapy, CA + MMC combination therapy and CA + NCS (4,000) therapy, respectively, combination therapy of CA and CQ producing the highest percentage of side effects.
PubMed ID: 6233856
Appears in Collections:Vol.29 No.3

Show full item record

Export to RefWorks

Export Format: 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.